Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:56:46.315Z.
Calculation as of: 2026-10-06T16:56:46.315Z.
Quote observation: 2026-10-06T16:55:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 31946573a42b73cd13b381604bc2f467f5098c78190e00cee0d2639f3054c777
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
4D Molecular Therapeutics, Inc.
Market Cap
$666.57M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$668.53M
EV/EBIT Ratio
61.04x
TTM Avg
21.67x
3Y Avg
25.85x
5Y Avg
35.25x
Market Cap
$688.89M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $666.57M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $668.53M | 61.04x | 21.67x | 25.85x | 35.25x |
| Starling Oncology, Inc. (STLN)vs › | $660.39M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $673.46M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $674.21M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.76M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $649.48M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $688.89M | N/A | N/A | N/A | N/A |
| SOPHiA GENETICS S.A. (SOPH)vs › | $632.99M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $632.00M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
